clinical trial · NCT05952869
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Merck Sharp & Dohme LLC·phase3·completed·n = 303
HypercholesterolemiaFamilial HypercholesterolemiaEnlicitide DecanoatePlacebo
brief summary
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
started
Aug 8, 2023
primary completion
Apr 7, 2025
completion
Apr 7, 2025
last updated
Feb 24, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol